Realist 2017

October 24-26, 2017
Brisbane, Australia
Janice Lee, Project Manager Paediatric HIV/HCV, DNDi presented on the paediatric HIV RELIVING Study.

Daiichi Sankyo announces collaborative research on drugs for neglected diseases

[Tokyo, Japan – March 30, 2017]
Daiichi Sankyo announces collaborative research on drugs for neglected diseases
Daiichi Sankyo Company, Limited (hereafter, “Daiichi Sankyo”), announced that it has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (hereafter, “DNDi”) with regard to a new research program, the Hit-to-Lead Project, with the aim to develop drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.

Study confirms key therapeutic advance for children living with HIV and tuberculosis

[Seattle, USA – February 14, 2017]
Landmark study proves that “super-boosting” approach counters negative interaction between key HIV and TB drugs
The non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) has released results of a study in South Africa that will make it easier for healthcare workers to treat children living with HIV who are co-infected with tuberculosis.

IMTechCon 2017

October 4-6, 2017
Chandigarh, India
Graeme Bilbe, R&D Director, DNDi and Suman Rijal, Director of DNDi Regional Office India took part in the event.

ReAct

Action on Antibiotic Resistance (ReAct) Africa Annual Conference 2017

September 18-19, 2017
Machakos, Kenya
DNDi Africa’s Director, Monique Wasunna, gave a presentation on DNDi‘s various programme models.

The 7th KASH Conference

KEMRI Annual Scientific and Health Conference

February 8-10, 2017
Nairobi, Kenya
Gina Ouattara, Project Coordinator for HIV/HCV, and Kevin Onyango, Project Coordinator for Mycetoma, both from the DNDi Africa office, presented at the event.

2016 in Review

Our staff, partners, and stakeholders share their highlights from 2016.